This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: How to Value a Stock

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- There's more than one way to value a stock, Jim Cramer told his "Mad Money" TV show viewers Thursday. Sticking to just one of those ways will only cost you money.

Cramer said he's been racking his brain trying to figure out why some commentators hate the markets of late. But then it hit him -- valuation. There's more than one way for stocks to rise, but to many analysts and pundits there's only one way, and that's growth.

Stocks like Walt Disney (DIS) exemplify this model, said Cramer. The company has become a regular outperformer, delivering consistent growth and dividends that shareholders can depend on.

Contrast that to a stock like Monster Beverage (MNST), which is rising because investors are simply willing to pay more for the earnings the company already has. This is called multiple expansion, and the pundits hate it.

But stocks can be valued other ways as well, such as on enterprise value, or what another company is willing to pay on a takeover. Then there are stocks like Yelp (YELP) and Concur Technology (CNQR), which are rising on only the promise of increased sales.

Then there are the companies valued on dreams. Stocks like Tesla Motors (TSLA) and Solar City (SCTY) trade on what investors hope someday those companies will become.

Cramer said he doesn't condone all of these types of valuation, but investors still need to be aware of the many valuation models that are driving so many stocks in today's markets.

Executive Decision: Edward Lanphier

For his "Executive Decision" segment, Cramer spoke with Edward Lanphier, president and CEO of Sangamo BioSciences (SGMO - Get Report), a stock that was up 17% Thursday on positive news stemming from its clinical trials. Shares of Sangamo are up 145% since Cramer first recommended it 11 months ago.

Lanphier explained Sangamo is developing a genome editing platform that can repair or remove any gene in the body. While many of its treatments are still in Phase II testing, the prospects for HIV and genetic diseases is very exciting.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CSX $33.27 -0.12%
PF $40.37 0.12%
SGMO $14.91 -0.80%
AAPL $124.24 0.70%
FB $83.01 0.11%


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs